ijms-logo

Journal Browser

Journal Browser

Multi-omics Profiling: New Tools for Precision Medicine in Cancer Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (10 July 2024) | Viewed by 1811

Special Issue Editor


E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania “L. Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, Italy
Interests: cell death mechanisms; microRNAs; long non coding RNAs; biomarkers; nanotechnology; drug delivery; signal transduction; target therapy; cancer; circulating tumor cells; glioblastoma; prostate cancer; hepatocellular cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer development depends on complex interplays at the genomic, transcriptional, metabolic and proteomic levels. Multi-omics analysis has significantly improved our understanding of complex tumors by offering the opportunity to characterize cancer biology, heterogeneity and plasticity at many molecular levels. Indeed, combining multi-omics data is central to discover the fundamental molecular mechanisms underlying oncogenesis. Several omics approaches, such as genomics, transcriptomics, epigenomics, metabolomics and proteomics, are available to analyze various, complementary biological layers with high-throughput technological advances.

The integration of multiple omics techniques has introduced a novel paradigm in oncology, from tumor site classification to pan-cancer molecular classification, contributing to the discovery of next-generation diagnostics, biomarkers, and new therapeutic opportunities for precision medicine. This Special Issue aims to collect the most recent advances in multi-omics research, focusing on the latest innovations in multi-omics approaches for characterizing cancer biology and multi-omics data integration for the identification of prognostic and treatment-specific biomarkers, introducing personalized cancer therapy.

This special issue is supervised by Dr. Silvia Zappavigna and assisted by our Topical Advisory Panel Member Dr. Marianna Abate.

Dr. Silvia Zappavigna
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genomics
  • proteomics
  • biomarkers
  • multi-omics integration
  • precision therapy
  • transcriptomics
  • metabolomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 397 KiB  
Article
Implementing Massive Parallel Sequencing into Biliary Samples Obtained through Endoscopic Retrograde Cholangiopancreatography for Diagnosing Malignant Bile Duct Strictures
by Wonsuk Park, Jin Gwack and Joonhong Park
Int. J. Mol. Sci. 2024, 25(17), 9461; https://doi.org/10.3390/ijms25179461 - 30 Aug 2024
Viewed by 615
Abstract
Despite advancements in radiologic, laboratory, and pathological evaluations, differentiating between benign and malignant bile duct strictures remains a diagnostic challenge. Recent developments in massive parallel sequencing (MPS) have introduced new opportunities for early cancer detection and management, but these techniques have not yet [...] Read more.
Despite advancements in radiologic, laboratory, and pathological evaluations, differentiating between benign and malignant bile duct strictures remains a diagnostic challenge. Recent developments in massive parallel sequencing (MPS) have introduced new opportunities for early cancer detection and management, but these techniques have not yet been rigorously applied to biliary samples. We prospectively evaluated the Oncomine Comprehensive Assay (OCA) and the Oncomine Pan-Cancer Cell-Free Assay (OPCCFA) using biliary brush cytology and bile fluid obtained via endoscopic retrograde cholangiopancreatography from patients with bile duct strictures. The diagnostic performance of MPS testing was assessed and compared to the pathological findings of biliary brush cytology and primary tissue. Mutations in TP53, BRAF, CTNNB1, SMAD4, and K-/N-RAS identified in biliary brush cytology samples were also detected in the corresponding bile fluid samples from patients with extrahepatic cholangiocarcinoma. These mutations were also identified in the bile fluid samples, but with variant allele frequencies lower than those in the corresponding biliary brush cytology samples. In control patients diagnosed with gallstones, neither the biliary brush cytology samples nor the bile fluid samples showed any pathogenic mutations classified as tier 1 or 2. Our study represents a prospective investigation into the role of MPS-based molecular testing in evaluating bile duct strictures. MPS-based molecular testing shows promise in identifying actionable genomic alterations, potentially enabling the stratification of patients for targeted chemotherapeutic treatments. Future research should focus on integrating OCA and OPCCFA testing, as well as similar MPS-based assays, into existing surveillance and management protocols for patients with bile duct strictures. Full article
Show Figures

Figure 1

Back to TopTop